

NOT FOR DISTRIBUTION TO EUROPE OR US MEDIA

For Immediate Release

Daiichi Sankyo Company, Limited
National Institute of Biomedical Innovation
The University of Kitakyushu

Daiichi Sankyo Awarded a Japan Science and Technology Agency “Newly extended Technology transfer Program” Grant

Tokyo, Japan (June 11, 2014) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that a R&D project for a novel, versatile vaccine adjuvant (hereafter, development project) for the purpose of creating a novel vaccine has been awarded a “Newly extended Technology transfer Program” (hereafter, NexTEP) grant from the Japan Science and Technology Agency (hereafter JST) and development on the project started from June 1.

By utilizing this grant, Daiichi Sankyo will promote the development of a novel, versatile vaccine adjuvant to realize the practical application of the research moving forward aligned with the National Institute of Biomedical Innovation (hereafter, NIBIO; Adjuvant project leader, Ken J. Ishii) and the University of Kitakyushu (hereafter, UKK; Professor Kazuo Sakurai, Faculty of Environmental Engineering), whereby all three organizations (Daiichi Sankyo, NIBIO, and UKK) have the necessary research seeds for this development program.

Daiichi Sankyo, NIBIO, and UKK contribute to the protection and improvement of people’s health and hygiene and the enhancement and dissemination of preventive medicine in Japan by supplying vaccines that meet unmet medical needs.

About Adjuvant

Adjuvant is a general term for the component of vaccine formulation that enhances and/or modulates the immune response towards antigens, i.e., effective ingredient of vaccines.

About NexTEP

NexTEP of JST supports collaboration between industry and academia, leading to practical application of the seeds from research outcome in academia.

For inquiries about this press release:
Daiichi Sankyo Co., Ltd. Corporate Communications Department Telephone: +81-3-6225-1126